Butylphthalide for Cognitive Impairment in Elderly Patients With Focal Epilepsy

Recruiting Phase 4 Interventional Study
Focal Epilepsy Cognitive Impairment
Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
60 – 85
Sex
Any
Trial phase
Phase 4
Study type
Interventional
Purpose
Treatment
Participants needed
220 (estimated)
Sponsor
First Affiliated Hospital of Wenzhou Medical University · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This is a multicenter, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of butylphthalide soft capsules for treating cognitive impairment in elderly patients with focal epilepsy. Study Population: 220 elderly patients (60-85 years) with focal epilepsy and mild to moderate cognitive impairment (Montreal Cognitive Assessment score 18-25). Intervention: Particip…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Age 60-85 years (inclusive) * Diagnosed with focal epilepsy according to ILAE 2025 latest classification standards, with disease duration ≥2 years * Currently receiving stable anti-seizure medication (ASM) treatment for ≥3 months, with good seizure control (monthly seizure fre…
Contacts

Huiqin Xu, MD

+86-13858806368

xuhuiqin@wmu.edu.cn

CONTACT

Jiahe Lin, PhD

+86-13587572321

linjiahe@wmu.edu.cn

CONTACT